Pharmaceutical products and services company Clinigen announced on Wednesday that non-executive director and chairman-designate Elmar Schnee was becoming chairman with immediate effect.
The AIM-traded firm said that at the same time, following its announcement on 13 July, Peter Allen was stepping down as chairman.
“I would like to thank Peter on behalf of the board, and personally, for his valued leadership and contributions since Clinigen’s initial public offering in 2012,” said chief executive officer Shaun Chilton.
“I have enjoyed working with Elmar to date and look forward to working more closely with him as we continue to grow the company and deliver value.”
New chairman Elmar Schnee said Clinigen had built a “strong” global business that was “uniquely well-positioned” to provide an end-to-end service to pharmaceutical clients.
“I look forward to continuing to work with the board and management as we build upon the company’s successes to date and realise the full potential of its lifecycle platform,” Schnee said.
Finally, departing chairman Peter Allen added that he was “proud” to have spent nine years at the helm of Clinigen’s board.
“During that time, the company has grown and developed into a global leader in providing global access to medicines, delivering significant value to patients, customers and shareholders.
“I have every confidence in Clinigen’s continued success.”
At 0854 BST, shares in Clinigen Group were up 0.72% at 630.5p.